SEPN

Insider Trades

Name	Value	Action	Price	Current Price
Shaikhly SamiraChief People Officer $86k2.9k shares SellJun 1, 2026 $29.66 --
Shaikhly SamiraChief People Officer $47k1.7k shares SellJun 1, 2026 $27.78 --
Shaikhly SamiraChief People Officer $39k1.3k shares SellJun 1, 2026 $28.79 --
Shaikhly SamiraChief People Officer $355k11.8k shares SellMay 26, 2026 $30.06 --
Bhatt ElizabethPresident And COO $61k2.6k shares SellApr 15, 2026 $23.76 --
Bhatt ElizabethPresident And COO $28k1.1k shares SellApr 15, 2026 $25.24 --

News

businesswire.comSepterna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meetingbusinesswire.comJun 8

seekingalpha.comSepterna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 13

zacks.comSepterna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimateszacks.comMay 11

globenewswire.comSepterna Highlights Business Progress and Reports First Quarter 2026 Financial Resultsglobenewswire.comMay 11

globenewswire.comSepterna to Present at Bank of America Securities Health Care Conferenceglobenewswire.comMay 5

Trade SEPN

About Septerna, Inc.

Septerna, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the identification and advancement of orally administered, small molecule therapies that modulate G protein-coupled receptors (GPCRs). The company's pipeline is designed to address a spectrum of conditions within endocrinology, immunology and inflammation, and metabolic disorders. Among its key programs, Septerna is developing SEP-786, an oral small molecule serving as a PTH1R agonist for individuals suffering from hypoparathyroidism. Another candidate, SEP-631, is an oral small molecule MRGPRX2 NAM aimed at treating chronic spontaneous urticaria and other mast cell-related ailments. Furthermore, its TSHR Program involves an oral small molecule TSHR NAM for both Graves' disease and thyroid eye disease. The company is also progressing oral small molecule single- and multi-incretin receptor agonists to tackle metabolic issues such as obesity and type 2 diabetes. Founded in 2019, Septerna, Inc. is headquartered in South San Francisco, California. It was formerly known as GPCR NewCo, Inc. until its rebranding to Septerna Inc. in June 2021.

CEO: Jeffrey T. Finer
IPO Date: Oct 25, 2024

Market Data

Open: $36.24
High: $37.32
Low: $34.51
Volume: 269.1K
Avg Volume: 318.2K
52W High: $37.32
52W Low: $10.23

Valuation

Market Cap: $1.6B
Enterprise Value: $1.6B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $110M
Revenue: $46M
Net Income: $-49M
Cash: $121M
Debt: $24M

Events

EarningsAug 10

EPS est. -0.42